CNSYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CERENOME, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.05 (-2.94%)
Close on Oct 19, 2026
- Market cap
- $11.38M
- P/E (TTM)
- –
- Dividend yield
- –
Cerenome statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Cerenome | Industry median |
|---|---|---|
| Market Cap | $12.52M | $230.55M |
| Enterprise Value | $3.94M | $202.97M |
| PS Ratio | 2.98 | 3.11 |
| PB Ratio | 2.29 | 3.14 |
| P/TBV Ratio | 2.46 | 4.57 |
Enterprise value
| Measure | Cerenome | Industry median |
|---|---|---|
| EV / Sales | 0.94 | 2.92 |
Income (trailing twelve months)
| Measure | Cerenome | Industry median |
|---|---|---|
| Revenue | $4.20M | $102.39M |
| Operating Income | -$26.40M | -$4.31M |
| Net Income | -$26.09M | -$6.57M |
| EBITDA | -$25.95M | -$1.98M |
Margins
| Measure | Cerenome | Industry median |
|---|---|---|
| Operating Margin | -628.1% | -6.04% |
| Profit Margin | -620.7% | -10.5% |
| EBITDA Margin | -617.3% | -2.67% |
| FCF Margin | -560.3% | -0.30% |
Returns
| Measure | Cerenome | Industry median |
|---|---|---|
| Return on Equity (ROE) | -614.1% | -19.2% |
| Return on Assets (ROA) | -214.0% | -13.3% |
| Return on Capital Employed (ROCE) | -483.3% | -9.07% |
Growth
| Measure | Cerenome | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -21.0% | 8.85% |
Balance sheet
| Measure | Cerenome | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.59M | $37.33M |
| Net Cash (Debt) | $8.59M | $3.92M |
| Net Cash Per Share | $1.13 | $0.28 |
| Equity (Book Value) | $5.46M | $57.36M |
| Book Value Per Share | $0.72 | $2.81 |
| Tangible Book Value | $5.09M | $10.71M |
| Working Capital | $3.20M | $54.64M |
Financial position
| Measure | Cerenome | Industry median |
|---|---|---|
| Current Ratio | 1.37 | 2.50 |
| Quick Ratio | 1.00 | 1.54 |
| Interest Coverage | -1200.00 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Cerenome | Industry median |
|---|---|---|
| Operating Cash Flow | -$22.18M | -$653.46K |
| Capital Expenditures | -$1.37M | -$3.69M |
| Free Cash Flow | -$23.55M | -$835.02K |
| FCF Per Share | -$3.10 | -$0.02 |
Efficiency
| Measure | Cerenome | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.59 |
| Revenue Per Employee | $150.11K | $322.57K |
| Profits Per Employee | -$931.71K | -$51.88K |
| Employee Count | 28 | 185 |
Dividends and yields
| Measure | Cerenome | Industry median |
|---|---|---|
| Earnings Yield | -208.3% | -6.91% |
| FCF Yield | -188.0% | -0.56% |
Shares
| Measure | Cerenome | Industry median |
|---|---|---|
| Shares Outstanding | 7,589,630 | 44,856,700 |
| Shares Change (YoY) | 146.3% | 3.35% |
| Shares Change (QoQ) | -95.7% | 0.27% |
| Float | 7,297,340 | 37,097,900 |
| Shares Held by Insiders | 3.85% | 10.6% |
| Shares Held by Institutions | 8.30% | 63.5% |
Scores
| Measure | Cerenome | Industry median |
|---|---|---|
| Altman Z-Score | -57.83 | 1.95 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from Cerenome's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.